Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 30;17(9):1515.
doi: 10.3390/cancers17091515.

Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Common Mutations: New Strategies

Brigida Stanzione  1 , Alessandro Del Conte  1 , Elisa Bertoli  1 , Elisa De Carlo  1 , Martina Bortolot  1   2 , Sara Torresan  1   2 , Michele Spina  1 , Alessandra Bearz  1
Affiliations
Review

Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Common Mutations: New Strategies

Brigida Stanzione et al. Cancers (Basel). .

Abstract

Epidermal growth factor receptor (EGFR) mutations are described in 10-15% of Caucasian patients and in 50% of Asian patients with non-squamous non-small cell lung cancer (NSCLC). The introduction of tyrosine kinase inhibitors (TKIs) has revolutionized the therapeutic scenario and has changed the natural history of the disease. Despite the results obtained with osimertinib, a third-generation TKI, most patients experience disease progression. The search for new therapeutic strategies both to enhance first-line treatment and to ensure adequate second-line therapies represents an unmet medical need, towards which all efforts are being concentrated. In this review, we describe the main strategies identified to improve the prognosis of patients with EGFR-mutated NSCLC.

Keywords: EGFR mutation; non-small cell lung cancer; target therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Main new strategies in EGFR-mutated NSCLC: novel approaches for EGFR-mutated NSCLC involve either using new therapies or improving existing ones by adding other drugs.
See this image and copyright information in PMC

References

    1. Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I., Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2024;74:229–263. doi: 10.3322/caac.21834. - DOI - PubMed
    1. LoPiccolo J., Gusev A., Christiani D.C., Jänne P.A. Lung cancer in patients who have never smoked—An emerging disease. Nat. Rev. Clin. Oncol. 2024;21:121–146. doi: 10.1038/s41571-023-00844-0. - DOI - PMC - PubMed
    1. Castellanos E., Feld E., Horn L. Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR -Mutated Non–Small Cell Lung Cancer. J. Thorac. Oncol. 2017;12:612–623. doi: 10.1016/j.jtho.2016.12.014. - DOI - PubMed
    1. Hendriks L., Kerr K., Menis J., Mok T., Nestle U., Passaro A., Peters S., Planchard D., Smit E., Solomon B., et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2023;34:339–357. doi: 10.1016/j.annonc.2022.12.009. - DOI - PubMed
    1. Gristina V., Malapelle U., Galvano A., Pisapia P., Pepe F., Rolfo C., Tortorici S., Bazan V., Troncone G., Russo A. The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal. Cancer Treat. Rev. 2020;85:101994. doi: 10.1016/j.ctrv.2020.101994. - DOI - PubMed

LinkOut - more resources